Enzymatic DNA synthesis is a well-established technique of DNA synthesis that is useful in synthetic biology, genetic engineering, therapeutic antibodies, vaccine design, and other advanced biological techniques. It is also very helpful to maintain the DNA library and custom DNA synthesis. Major factors driving the market growth include the rising prevalence of genetic disorders and the surging number of product launches. Additionally, growing demand for personalized medicine and DNA data storage is likely to emerge as a significant future trend in the market during the forecast period.

The enzymatic DNA synthesis market is comprised of top players involving Telesis Bio Inc; Evonetix; Ansa Biotechnologies, Inc.; Camena Bio; GenScript Biotech Corp.; Molecular Assemblies; DNA Script; Touchlight; Synbio Technologies; and Twist Bioscience; and others. The companies have been implementing various strategies that have helped their growth and, in turn, brought about several breakthroughs and transitions in the industry. The companies have utilized organic strategies such as launches, expansion, and product approvals. Moreover, the market players have also deployed several utilized inorganic strategies, including mergers & acquisitions, partnerships, and collaborations.

Below are the major growth strategies undertaken by the players operating in the global enzymatic DNA synthesis market:




Codex DNA, Inc., announced a plan to change its Company name to Telesis Bio. The innovative and pioneering spirit, versatility, and power of the Company’s technologies have enabled them to expand its portfolio to include an array of tools for both synthetic biology and genomics applications, and to reflect the expansion, an initiative to a change name to Telesis Bio was taken.


Touchlight entered into a non-exclusive patent license agreement with Pfizer. Under the license agreement, Pfizer has rights to Touchlight’s enzymatic dbDNA patent portfolio for worldwide use in Pfizer’s manufacture and commercialization of its mRNA-based vaccines, therapeutics, and gene therapies. The agreement includes an upfront payment, clinical and commercial milestone payments, and royalties to Touchlight upon commercialization.


Molecular Assemblies, Inc. and Codexis, Inc. announced an update on their partnership to engineer enzymes to deliver differentiated solutions for the enzymatic synthesis of DNA. A highly evolved DNA polymerase (of Codexis) is used to develop a high-performing enzyme to enable Molecular Assemblies’ Fully Enzymatic Synthesis (FES) and access to Key Customer Program.


DNA Script obtained the CE marking for its SYNTAX System, the first EDS-powered benchtop DNA printer. With the marking, the SYNTAX System meets EU safety, health, and environmental protection guidelines, and the Company can begin commercial sales of the SYNTAX System in European countries.

Read More:

Leave a Reply

Your email address will not be published. Required fields are marked *